SFTPD and psoriasis: Infliximab, which is a TNF-α monoclonal antibody applied in psoriasis treatments, appears to inhibit SP-D in murine models of intestinal ischemia/reperfusion or lung injury and relieve tissue injury by decreasing SP-D levels (108).